Pfizer vaccine effectiveness declines faster than AstraZeneca – study

The findings, which have not yet been peer reviewed, also suggest that those infected with the Delta variant after their second jab had similar peak levels of virus to unvaccinated people

Researchers said they could not comment on what the study might mean for the potential autumn booster campaign (Jacob King/PA)

Two doses of the Pfizer/BioNTech vaccine appears to have greater effectiveness initially against new Covid-19 infections associated with the Delta variant when compared to the Oxford/AstraZeneca jab, but its efficacy also declines faster, preliminary research suggests.

Scientists from the University of Oxford have said that after four to five months, the level of protection offered by both vaccines is similar, with the AstraZeneca jab maintaining its effectiveness throughout the duration.